Small Cancer Drug Makers Are on Fire

In case some didn’t get the memo, the smaller drug makers have been on fire this summer.

On July 7, the Lucky 13 Buys list was unleashed. Since that time, SuperGen (SUPG) and Ariad Pharamaceuticals (ARIA) have each topped the list with gains of 45% and 85%, respectively. In recent sessions, both SUPG and ARIA have pulled back.

On Monday August 3, Lucky 13 Buys was a mere four weeks old. So far, the results have been impressive and far exceeding prior expectations. Five have advanced more than 30%. Nine are up over 20%, and 12 of the Lucky 13 Buys have increased by more than 13%.